Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.


U.S. Senate Passes Bill to Improve Cancer Drugs for Children

Washington, DC, August 7, 2017 — Ledyard King reports in USA Today that, until now, drug companies have been free to decide whether to pursue treatments for pediatric cancers as part of their work on adult cancers.

They won’t have much choice going forward.

The Senate on August 3 overwhelmingly passed legislation requiring the pharmaceutical industry to expend more resources on treatment for childhood cancers. Continue reading

New Jersey Department of Health Recognizes National Infant Immunization Week

Trenton, NJ, April 23, 2017 — The New Jersey Department of Health and local health partners are promoting the importance of protecting infants from vaccine-preventable diseases during National Infant Immunization Week (NIIW) with events across the state.

NIIW, an annual observance highlighting the achievements of immunization programs and partners in promoting healthy communities, will be celebrated April 22 through 29.

“The best way to protect infants from 14 serious childhood diseases, like whooping cough and measles, is to make sure they receive recommended immunizations,” Health Commissioner Cathleen D. Bennett said. “This week serves as a reminder for parents to be sure their child is up-to-date on all recommended vaccines.” Continue reading

Pharmalot: FDA Wants to Nix Voucher Program for Rare Pediatric Disease Drugs

STAT PharmalotBoston, MA, March 7, 2016 ― Pharmalot reporter-blogger Ed Silverman reports in STAT that the Food and Drug Administration (FDA) wants to end a voucher program designed to spur development of new drugs for rare pediatric diseases, although a new government report released on Wednesday said it’s too early to say whether it’s working.

Drug makers and advocacy groups, however, told the Government Accountability Office they see value in the program, which expires on Oct. 1.

At issue are pediatric review vouchers.  Created in 2012, the program awards a priority review voucher to a drug maker that wins approval of a treatment for a rare pediatric disease. Companies can later redeem vouchers when seeking approval for another medicine to treat any illness. Continue reading